Tag - NGEN

Developments

NervGen completes EOP2 meeting and aligns with FDA on Phase 3 study

NervGen Pharma (NASDAQ: NGEN) has announced the completion of a successful end-of-Phase 2 (EOP2) meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for...

April 7, 2026

Executive Moves

NervGen appoints Michael Kelly as president, CEO

NervGen Pharma (TSXV:NGEN; OTCQX:NGENF) named Michael Kelly to the position of president and CEO, effective April 10, as well as a member of the board. In a statement, Bill Radvak, executive chairman of NervGen, said Mr...

April 10, 2023

Executive Moves

Paul Brennan steps down as CEO of NervGen

Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...

September 23, 2022

Developments

NervGen NVG-291-R posts significant preclinical functional repair from stroke

The University of Cincinnati and Case Western Reserve University published a pioneering preclinical study in the peer-reviewed scientific journal, Cell Reports, demonstrating that NervGen Pharma‘s (TSXV:NGEN;...

July 28, 2022

Tag - NGEN

NervGen completes EOP2 meeting and aligns with FDA on Phase 3 study

NervGen appoints Michael Kelly as president, CEO

Paul Brennan steps down as CEO of NervGen

NervGen NVG-291-R posts significant preclinical functional repair from stroke

Subscribe